Trial intelligence / Profile preview

Chemoradiation and/or Accelerated Radiation in NPC

NCT00563862Phase 3Terminated

Sponsor
Hospital Authority
Start
Jul 1999
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, randomised, open-label trial of cisplatin and fluorouracil in nasopharyngeal carcinoma (NPC) (4 arms), sponsored by Hospital Authority. Primary endpoint: Failure free survival rate. Started Jul 1999; status: terminated.

02

Drugs

cisplatinfluorouracil
03

Conditions

nasopharyngeal carcinoma (NPC)

Beyond the preview

Go deeper on NCT00563862.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00563862.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call